Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vMyx-M11KO-IL15Rα
- Development stage
- Preclinical
- Lead developer
- OncoMyx Therapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
vMyx-M11KO-IL15Rα is an engineered oncolytic myxoma virus (MYXV) designed for the treatment of solid tumors. It is genetically modified to lack the viral anti-apoptotic Bcl2 homolog M11L gene (M11KO) and is armed to express the interleukin-15 (IL-15) and interleukin-15 receptor alpha (IL-15Rα) cytokine complex. The deletion of the M11L gene enhances the oncolytic activity of the virus, while the expression of the IL-15/IL-15Rα complex promotes the recruitment, activation, and proliferation of CD8+ effector memory T cells and natural killer (NK) cells within the tumor microenvironment. Preclinical studies, including those in combination with the XPO-1 inhibitor selinexor, have demonstrated significant reduction in tumor burden and prolonged survival, showing a robust abscopal effect against distal untreated tumors.
- Other names
- vMyx-M11KO-IL15RavMyx-M-11KO-IL15RavMyx-M 11KO-IL15RavMyx-M11LKO-IL15RavMyx-M-11LKO-IL15RavMyx-M 11LKO-IL15RavMyx-M11LKO-IL15Rα
02
Targets
CD4 (T lymphocyte surface antigen)CD8A (CD8 alpha/beta Coreceptor)IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)
Beyond the preview
Go deeper on vMyx-M11KO-IL15Rα.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vMyx-M11KO-IL15Rα.